Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The aim of this study is to evaluate the potential of BHB supplementation as a novel strategy to impede the development and progression of intestinal adenomas in individuals with FAP, thus potentially reducing the need for frequent upper endoscopies and colonoscopies and preventing the need for risk-reducing surgical intervention.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-09-20
Completion Date
2027-10
Last Updated
2025-09-04
Healthy Volunteers
No
Conditions
Interventions
R-1,3-Butanediol (10G-A)
Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks
R-1,3-Butanediol (20G-A)
Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks
R-1,3-Butanediol (30G-A)
Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks
R-1,3-Butanediol (30G-B)
Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth three times per day (30 total grams of R-1,3-Butanediol) for 12 weeks, with a possible additional 12 week extension
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States